Journal of Microbiology

Ki Tae Suk

2 Articles

Gut Lactobacillus and Probiotics Lactobacillus lactis/rhamnosis Ameliorate Liver Fibrosis in Prevention and Treatment: Sung Min Won , Na Young Lee , Ki&# , Haripriya Gupta , Satya Priya Sharma , Kyung Hwan Kim , Byoung Kook Kim , Hyun Chae Joung , Jin Ju Jeong , Raja Ganesan , Sang Hak Han , Sang Jun Yoon , Dong Joon Kim , Ki Tae Suk; J. Microbiol. 2023;61(2):245-257. Published online February 6, 2023; DOI: https://doi.org/10.1007/s12275-023-00014-y

88 View
0 Download
8 Web of Science
8 Crossref

The progression and exacerbation of liver fibrosis are closely related to the gut microbiome. It is hypothesized that some probiotics may slow the progression of liver fibrosis. In human stool analysis [healthy group (n = 44) and cirrhosis group (n = 18)], difference in Lactobacillus genus between healthy group and cirrhosis group was observed. Based on human data, preventive and therapeutic effect of probiotics Lactobacillus lactis and L. rhamnosus was evaluated by using four mice fibrosis models. L. lactis and L. rhamnosus were supplied to 3,5-diethoxycarbonyl-1,4-dihydrocollidine or carbon tetrachloride-induced liver fibrosis C57BL/6 mouse model. Serum biochemical measurements, tissue staining, and mRNA expression in the liver were evaluated. The microbiome was analyzed in mouse cecal contents. In the mouse model, the effects of Lactobacillus in preventing and treating liver fibrosis were different for each microbe species. In case of L. lactis, all models showed preventive and therapeutic effects against liver fibrosis. In microbiome analysis in mouse models administered Lactobacillus, migration and changes in the ratio and composition of the gut microbial community were confirmed. L. lactis and L. rhamnosus showed preventive and therapeutic effects on the progression of liver fibrosis, suggesting that Lactobacillus intake may be a useful strategy for prevention and treatment.

Citations

Citations to this article as recorded by

Probiotics modulation of the endotoxemic effect on the gut and liver of the lipopolysaccharide challenged mice
Gyan Babu, Banalata Mohanty
Drug and Chemical Toxicology.2025; 48(3): 627. CrossRef
Enhancing the application of probiotics in probiotic food products from the perspective of improving stress resistance by regulating cell physiological function: A review
Dingkang Wang, Ruijie Xu, Sha Liu, Xiaomin Sun, Tianxiao Zhang, Lin Shi, Youfa Wang
Food Research International.2025; 199: 115369. CrossRef
Lactobacillus gasseri BNR17 and Limosilactobacillus fermentum ABF21069 Ameliorate High Sucrose-Induced Obesity and Fatty Liver via Exopolysaccharide Production and β-oxidation
Yu Mi Jo, Yoon Ji Son, Seul-Ah Kim, Gyu Min Lee, Chang Won Ahn, Han-Oh Park, Ji-Hyun Yun
Journal of Microbiology.2024; 62(10): 907. CrossRef
Research reviews and prospects of gut microbiota in liver cirrhosis: a bibliometric analysis (2001–2023)
Xiaofei Zhu, Ziyuan Zhou, Xiaxia Pan
Frontiers in Microbiology.2024;[Epub] CrossRef
Gut microbes combined with metabolomics reveal the protective effects of Qijia Rougan decoction against CCl4-induced hepatic fibrosis
Xue Li, Xinyi Xu, Sian Tao, Yue Su, Li Wen, Dong Wang, Jibin Liu, Quansheng Feng
Frontiers in Pharmacology.2024;[Epub] CrossRef
Assessment of probiotic properties of lactic acid bacteria isolated from an artisanal Colombian cheese
Samantha Roldán-Pérez, Sara Lucía Gómez Rodríguez, José Uriel Sepúlveda-Valencia, Orlando Simón Ruiz Villadiego, María Elena Márquez Fernández, Olga I. Montoya Campuzano, Mónica María Durango-Zuleta
Heliyon.2023; 9(11): e21558. CrossRef
Agrocybe aegerita Polysaccharide Combined with Bifidobacterium lactis Bb-12 Attenuates Aging-Related Oxidative Stress and Restores Gut Microbiota
Xiaoyan Liu, Yanyu Feng, Hongmin Zhen, Lina Zhao, Hongqiang Wu, Bin Liu, Guangsen Fan, Aijun Tong
Foods.2023; 12(24): 4381. CrossRef
Probiotics and liver fibrosis: An evidence-based review of the latest research
Lin Cheng, Jianyou Shi, Haoyuan Peng, Rongsheng Tong, Yonghe Hu, Dongke Yu
Journal of Functional Foods.2023; 109: 105773. CrossRef

[MINIREVIEW] Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics: Min Seok Cho , Sang Yeol Kim , Ki Tae Suk , Byung-Yong Kim; J. Microbiol. 2018;56(12):855-867. Published online October 25, 2018; DOI: https://doi.org/10.1007/s12275-018-8346-2

70 View
0 Download
29 Web of Science
28 Crossref

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most common types of liver diseases worldwide and its incidence continues to increase. NAFLD occurs when the body can no longer effectively store excess energy in the adipose tissue. Despite the increasing prevalence of NAFLD, making lifestyle changes, including increased exercise, is often an elusive goal for patients with NAFLD. The liver directly connects to the gut-gastrointestinal milieu via the portal vein, which are all part of the gut-liver axis. Therefore, the gut-microbiome and microbial products have been actively studied as likely key factors in NAFLD pathophysiology. Hence, dysbiosis of the gut microbiome and therapeutic manipulation of the gut-liver axis are being investigated. Novel therapeutic approaches for modulating gut microbiota through the administration of probiotics, prebiotics, synbiotics, and antibiotics have been proposed with numerous promising initial reports on the effectiveness and clinical applications of these approaches. This review delves into the current evidence on novel therapies that modulate gut microbiota and discusses ongoing clinical trials targeting the gut-liver axis for the management and prevention of NAFLD.

Citations

Citations to this article as recorded by

Schisandra chinensis lignans ameliorate hepatic inflammation and steatosis in methionine choline-deficient diet-fed mice by modulating the gut-liver axis
Li-Shan Yan, Jian-Ying Kang, Chun-Yu Gu, Xin-Yu Qiu, Jia-Jia Li, Brian Chi-Yan Cheng, Yi-Wei Wang, Gan Luo, Yi Zhang
Journal of Ethnopharmacology.2025; 348: 119801. CrossRef
ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease
Ashwani K. Singal, Robert J. Wong, Srinivasan Dasarathy, Manal F. Abdelmalek, Brent A. Neuschwander-Tetri, Berkeley N. Limketkai, Jessica Petrey, Craig J. McClain
American Journal of Gastroenterology.2025; 120(5): 950. CrossRef
Highland barley β-glucan supplementation attenuated hepatic lipid accumulation in Western diet-induced non-alcoholic fatty liver disease mice by modulating gut microbiota
Huicui Liu, Chenxi Nie, Xinzhong Hu, Juxiu Li
Food & Function.2024; 15(3): 1250. CrossRef
Therapeutic applications of melatonin in disorders related to the gastrointestinal tract and control of appetite
Atousa Moghadam Fard, Pardis Goodarzi, Mehran Mottahedi, Setareh Garousi, Hamed Zadabhari, Mohammad Kalantari Shahijan, Saeedeh Esmaeili, Mohsen Nabi-Afjadi, Bahman Yousefi
Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(8): 5335. CrossRef
Bifidobacterium lactis Probio‐M8 prevents nonalcoholic fatty liver disease in high‐fat diet‐fed rats: The potential role in modulating gut microbiota
Wen Fan, Kairui Tang, Yuanjun Deng, Chuiyang Zheng, Maoxing Pan, Dajin Pi, Zheng Liang, Jianwei Zhen, Qinhe Yang, Yupei Zhang
Food Bioengineering.2024; 3(1): 29. CrossRef
Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges
Ernesto Saenz, Nathally Espinosa Montagut, Baohong Wang, Christoph Stein-Thöringer, Kaicen Wang, Honglei Weng, Matthias Ebert, Kai Markus Schneider, Lanjuan Li, Andreas Teufel
Engineering.2024; 40: 51. CrossRef
The gut-liver axis in fatty liver disease: role played by natural products
Zhu Ming, Xie Ruishi, Xu Linyi, Yang Yonggang, Luo Haoming, Lan Xintian
Frontiers in Pharmacology.2024;[Epub] CrossRef
Dietary fiber intake and mortality among survivors of liver cirrhosis: A prospective cohort study
Zahra Hariri, Azita Hekmatdoost, Fereshteh Pashayee-khamene, Sara Karimi, Salehe Ahmadzadeh, Zahra Yari
Heliyon.2023; 9(6): e16170. CrossRef
The Activity of Prebiotics and Probiotics in Hepatogastrointestinal Disorders and Diseases Associated with Metabolic Syndrome
Alicia Rodríguez-Pastén, Nury Pérez-Hernández, Javier Añorve-Morga, Rubén Jiménez-Alvarado, Raquel Cariño-Cortés, Teresa Sosa-Lozada, Eduardo Fernández-Martínez
International Journal of Molecular Sciences.2022; 23(13): 7229. CrossRef
Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines
Anwesha Gangopadhyay, Radwa Ibrahim, Karli Theberge, Meghan May, Karen L. Houseknecht
Frontiers in Neuroscience.2022;[Epub] CrossRef
Multi-Omics Nutritional Approaches Targeting Metabolic-Associated Fatty Liver Disease
Omar Ramos-Lopez
Genes.2022; 13(11): 2142. CrossRef
Construction of two new polyoxometalate complexes and their recyclability in photodegradation of cephalexin and ceftiofur
Qian-Qian Wang, Li-Hui Mao, Da-Xiang Wang, Yan-Mei Ma, Xin-Li Shi, Xi-Hao Tian
Inorganica Chimica Acta.2022; 536: 120902. CrossRef
Gut–Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers
Antonio Gil-Gómez, Paola Brescia, Maria Rescigno, Manuel Romero-Gómez
Seminars in Liver Disease.2021; 41(02): 191. CrossRef
Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome
Carolina Castillo-Castro, Alexandro José Martagón-Rosado, Rocio Ortiz-Lopez, Luis Felipe Garrido-Treviño, Melissa Villegas-Albo, Francisco Javier Bosques-Padilla
World Journal of Hepatology.2021; 13(11): 1494. CrossRef
Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls
Ditte Marie Kirkegaard-Klitbo, Flemming Bendtsen, Jens Lundgren, Robert J de Knegt, Klaus Fuglsang Kofoed, Susanne Dam Nielsen, Thomas Benfield
The Journal of Infectious Diseases.2021; 224(3): 443. CrossRef
Citrulline supplementation attenuates the development of non-alcoholic steatohepatitis in female mice through mechanisms involving intestinal arginase
Dragana Rajcic, Anja Baumann, Angélica Hernández-Arriaga, Annette Brandt, Anika Nier, Cheng Jun Jin, Victor Sánchez, Finn Jung, Amélia Camarinha-Silva, Ina Bergheim
Redox Biology.2021; 41: 101879. CrossRef
Gut metabolites and inflammation factors in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Xiongfeng Pan, Shi Wu Wen, Atipatsa C. Kaminga, Aizhong Liu
Scientific Reports.2020;[Epub] CrossRef
Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view
Hui-Ting Chen, Hong-Li Huang, Yong-Qiang Li, Hao-Ming Xu, Yong-Jian Zhou
World Journal of Gastroenterology.2020; 26(16): 1901. CrossRef
LactobacillusandPediococcusameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome
Na Young Lee, Sang Jun Yoon, Dae Hee Han, Haripriya Gupta, Gi Soo Youn, Min Jea Shin, Young Lim Ham, Min Jung Kwak, Byung Yong Kim, Jeong Seok Yu, Do Yup Lee, Tae-Sik Park, Si-Hyun Park, Byoung Kook Kim, Hyun Chae Joung, In Suk Choi, Ji Taek Hong, Dong Jo
Gut Microbes.2020; 11(4): 882. CrossRef
Macrophages in the pathophysiology of NAFLD: The role of sex differences
Stefano Ministrini, Fabrizio Montecucco, Amirhossein Sahebkar, Federico Carbone
European Journal of Clinical Investigation.2020;[Epub] CrossRef
IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
Sebastião Mauro Bezerra DUARTE, José Tadeu STEFANO, Denise Siqueira VANNI, Flair José CARRILHO, Claudia Pinto Marques Souza de OLIVEIRA
Arquivos de Gastroenterologia.2019; 56(4): 431. CrossRef
Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
Sebastião M.B. Duarte, Jose Tadeu Stefano, Claudia P. Oliveira
Annals of Hepatology.2019; 18(3): 416. CrossRef
Aged garlic extract ameliorates fatty liver and insulin resistance and improves the gut microbiota profile in a mouse model of insulin resistance
Toshio Maeda, Satomi Miki, Naoaki Morihara, Yoshiyuki Kagawa
Experimental and Therapeutic Medicine.2019;[Epub] CrossRef
Microbiota and nonalcoholic fatty liver disease
Christelle Knudsen, Audrey M. Neyrinck, Nicolas Lanthier, Nathalie M. Delzenne
Current Opinion in Clinical Nutrition & Metabolic Care.2019; 22(5): 393. CrossRef
Gold Nanoparticles Cure Bacterial Infection with Benefit to Intestinal Microflora
Juanjuan Li, Ruitao Cha, Xiaohui Zhao, Hongbo Guo, Huize Luo, Mingzheng Wang, Fengshan Zhou, Xingyu Jiang
ACS Nano.2019; 13(5): 5002. CrossRef
Role of Gut Microbiota in Hepatocarcinogenesis
Haripriya Gupta, Gi Soo Youn, Min Jea Shin, Ki Tae Suk
Microorganisms.2019; 7(5): 121. CrossRef
The Prenatal Microbiome: A New Player for Human Health
Valeria D’Argenio
High-Throughput.2018; 7(4): 38. CrossRef
Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease
David Porras, Esther Nistal, Susana Martínez-Flórez, Javier González-Gallego, María Victoria García-Mediavilla, Sonia Sánchez-Campos
Frontiers in Physiology.2018;[Epub] CrossRef

Ki Tae Suk

1 Article

Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease: Sang Yoon Lee, Su-Been Lee, Goo-Hyun Kwon, Seol Hee Song, Jeong Ha Park, Min Ju Kim, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Satya Priya Sharma, Ki Tae Suk; J. Microbiol. 2025;63(2):e2411002. Published online February 27, 2025; DOI: https://doi.org/10.71150/jm.2411002

767 View
55 Download

Abstract PDF: Synbiotics have become a new-age treatment tool for limiting the progression of metabolic dysfunction-associated steatotic liver disease; however, inclusive comparisons of various synbiotic treatments are still lacking. Here, we have explored and evaluated multiple synbiotic combinations incorporating three distinctive prebiotics, lactitol, lactulose and fructooligosaccharides. Of the synbiotic treatments evaluated, a combination of fructooligosaccharides and probiotics (FOS+Pro) exhibited superior protection against western diet-induced liver degeneration. This synbiotic (FOS+Pro) combination resulted in the lowest body weight gains, liver weights and liver/body weight ratios. The FOS+Pro synbiotic combination substantially alleviated liver histopathological markers and reduced serum AST and cholesterol levels. FOS+Pro ameliorated hepatic inflammation by lowering expression of proinflammatory markers including TNF-α, IL-1β, IL-6, and CCL2. FOS+Pro significantly improved steatosis by restricting the expression of lipid metabolic regulators (ACC1, FAS) and lipid transporters (CD36) in the liver. These findings are critical in suggesting that synbiotic treatments are capable of restraining western diet-induced metabolic dysfunction in the liver. Additionally, this study demonstrated that adding probiotic strains amplified the effectiveness of fructooligosaccharides but not all prebiotics.

Author index